Nanoliposomal Dry Powder Formulations

Methods in Enzymology

Volumn 464, Issue C, 2009, Pages 167-191

  Patel, Gaurang ^a   Chougule, Mahavir ^b   Singh, Mandip ^b   Misra, Ambikanandan ^a  

^a Faculty of Technology and Engineering   (India)

^b FLORIDA A AND M UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMPHOTERICIN B; BUDESONIDE; CIPROFLOXACIN; DAPSONE; ISONIAZID; KETOTIFEN; LEUPRORELIN; LEVONORGESTREL; LIPOSOME; NANOCARRIER; RIFAMPICIN; TACROLIMUS;

AEROSOL; CALORIMETRY; CONE BEAM COMPUTED TOMOGRAPHY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; DRUG RETENTION; DRUG STABILITY; DRY POWDER; ENCAPSULATION; EX VIVO STUDY; FREEZE DRYING; HUMAN; IMAGE ANALYSIS; IN VITRO STUDY; IN VIVO STUDY; LUNG ALVEOLUS EPITHELIUM; LUNG DEPOSIT; LUNG PARENCHYMA; MACROPHAGE; MICROPHOTOGRAPHY; MOISTURE; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REVIEW; SCANNING ELECTRON MICROSCOPY; SPRAY DRYING; TIME; ANIMAL; ARTICLE; CHEMISTRY; METHODOLOGY; NANOTECHNOLOGY; POWDER;

ANIMALS; CHEMISTRY, PHARMACEUTICAL; HUMANS; LIPOSOMES; MICROSCOPY, ELECTRON, SCANNING; NANOTECHNOLOGY; PARTICLE SIZE; POWDERS;

EID: 71549145297     PISSN: 00766879     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0076-6879(09)64009-X     Document Type: Review

References (75)

1. Aerosols, Nasal Sprays, Metered Dose Inhalers, and Dry Powder Inhalers (2007) USP 30 NF 25; 601-607
2. Akwete L.A., and Hsu L. Leuprolide and other LH-RH analogues in stability and characterization of protein and peptide drugs: Case histories. In: Wang Y.J., and Pearlman R. (Eds). Formation, Characterization, and Stability of Protein Drugs (1993), Plenum Press, New York 159-199
3. Anabousi S., Bakowsky U., Schneider M., Huwer H., Lehr C.M., and Ehrhardt C. In vitro assessment of transferrin-conjugated liposomes as drug delivery systems for inhalation therapy of lung cancer. Eur. J. Pharm. Sci. 29 (2006) 367-374
4. Application Note by Malvern Instruments. Size and zeta potential characterization of anionic and cationic liposomes on the Zetasizer Nano
5. Ashurst I.I., Malton A., Prime D., and Sumby B. Latest advances in the development of dry powder inhalers. Pharm. Sci. Technol. 3 (2000) 246-256
6. Betagiri J.V., Jenkins S.A., and Parsons D.L. Liposomes Drug Delivery System (1993), Technomic Publishing Co. Inc., Lanchaster, Basel, Switzerland 7-20
7. Betagiri J.V., Jenkins S.A., and Parsons D.L. Liposomes Drug Delivery System (1993), Technomic Publishing Co. Inc., Lanchaster, Basel, Switzerland 21-24
8. Bisgaard H. Drug delivery from inhaler devices. Lung deposition, clinical effect and cost effectiveness vary. Br. Med. J. 313 (1996) 895-896
9. Bosquillona C., Rouxhetb P.G., Ahimoub F., Simonc D., Culotd C., Preata V., and Vanbever R. Aerosolization properties, surface composition and physical state of spray-dried protein powders. J. Control. Release 99 (2004) 357-367
10. Briscoe P., Caniggia I., Graves A., Benson B., Huang L., Tanswell A.K., and Freeman B.A. Delivery of superoxide dismutase to pulmonary epithelium via pH-sensitive liposomes. Am. J. Physiol. 268 (1995) L374-L380
11. Byron P.R., and Patton J.S. Drug delivery via the respiratory tract. J. Aerosol Med. 7 1 (1994) 49-75
12. Byron P.R., Roberts N.S.R., and Clark A.R. An isolated perfused rat lung preparation for the study of aerosolized drug deposition and absorption. J. Pharm. Sci. 75 (1986) 168-171
13. Carr R.L. Evaluating flow properties of solids. Chem. Eng. 72 (1965) 163-168
14. Chien Y.W. Novel Drug Delivery Systems, Drugs and the Pharmaceutical Sciences 50 (1992), Marcel Dekker, New York 797
15. Chougule M., Padhi B., and Misra A. Nano-liposomal dry powder inhaler of amiloride hydrochloride. J. Nanosci. Nanotechnol. 6 9-10 (2006) 3001-3009
16. Chougule M., Padhi B., and Misra A. Nano-liposomal dry powder inhaler of tacrolimus: Preparation, characterization, and pulmonary pharmacokinetics. Int. J. Nanomed. 2 4 (2007) 675-688
17. Chougule M., Padhi B., and Misra A. Development of spray dried liposomal dry powder inhaler of dapsone. AAPS PharmSciTech. 9 1 (2008) 47-53
18. Courrier H.M., Butz N., and Andamme F. Pulmonary drug delivery systems: Developments and prospects. Crit. Rev. Ther. Drug Carrier Syst. 19 4-5 (2002) 425-498
19. Elbert K.J., Schafer U.F., Schäfers H.J., Kim K.J., Lee V.H., and Lehr C.M. Monolayers of human alveolar epithelial cells in primary culture for pulmonary absorption and transport studies. Pharm. Res. 16 (1999) 601-608
20. Fang X., Song Y., Zemans R., Hirsch J., and Matthay M.A. Transport across cultured rat alveolar epithelial cells: A novel in vitro system. Am. J. Physiol. (Lung Cell Mol. Physiol.) 27 (2004) L104-L110
21. Fiegel J., Ehrhardt C., Schaefer U.F., Lehr C.M., and Hanes J. Large porous particle impingement on lung epithelial cell monolayers-Toward improved particle characterization in the lung. Pharm. Res. 20 5 (2003) 788-796
22. Fielding R.M., and Abra R.M. Factors affecting the release rate of terbutaline from liposome formulations after intratracheal instillation in the guinea pig. Pharm. Res. 9 (1992) 220-222
23. Fuchs S., Hollins A.J., Lehr C.M., et al. Differentiation of human alveolar epithelial cells in primary culture: Morphological characterization and synthesis of caveolin-1 and surfactant protein-C. Cell Tissue Res. 311 (2003) 31-45
24. Geller D.E. Comparing clinical features of the nebulizer, metered-dose inhaler, and dry powder inhaler. Respir. Care 50 10 (2005) 1313-1322
25. Goel B.K. Medical Laboratory Technology III (1988), Tata McGraw-Hill, New Delhi, India 1031
26. Hersey J.A. Ordered mixing: A new concept in powder mixing practice. Powder Technol. 11 (1975) 41-44
27. Hickey A.J. Summary of Common Approaches to Pharmaceutical Aerosol Administration; Pharmaceutical Inhalation Aerosol Technology (1992), Marcel Dekker, New York 255-288
28. Hickey A.J., Concessio N.M., Platz R.M., et al. Factors influencing the dispersion of dry powders as aerosols. Pharm. Technol. 8 (1994) 58-84
29. Hu C., and Rhodes D.G. Proniosomes: A novel drug carrier preparation. Int. J. Pharm. 185 (1999) 23-35
30. Hyung J.L., Eun C.C., Jongwon S., Do-Hoon K., Eun J.A., and Junoh K. Polymer-associated liposomes as a novel delivery system for cyclodextrin-bound drugs. J. Colloid Interface Sci. 320 (2008) 460-468
31. ICH Guidelines. Stability testing of new drug substances and products. ICH Topic Q 1 A (R2) (2003) Page 7 of 20 August 2003
32. Joshi M.R., and Misra A. Liposomal budesonide for dry powder inhaler: Preparation and stabilization. AAPS PharmSciTech. 2 4 (2001) 25-31
33. Joshi M., and Misra A. Dry powder inhalation of liposomal ketotifen fumarate: Formulation and characterization. Int. J. Pharm. 223 1-2 (2001) 15-27
34. Joshi M., and Misra A. Pulmonary disposition of budesonide from liposomal dry prowder inhaler. Meth. Find Exp. Clin. Pharm. 23 10 (2001) 531
35. Joshi M., and Misra A. Disposition kinetics of ketotifen from liposomal dry powder for inhalation in rat lung. Clin. Exp. Pharmacol. Physiol. 30 (2003) 153-156
36. Kadimi U.S., Balasubramanian D.R., Ganni U.R., Balaraman M., and Govindarajulu V. In vitro studies on liposomal amphotericin B obtained by supercritical carbon dioxide-mediated process. Nanomedicine 3 4 (2007) 273-280
37. Kaszuba M. The measurement of nanoparticles using photon correlation spectroscopy and avalanche photo diodes. J. Nano Res. 1 3 (1999) 405-409
38. Otake K., Imura T., Sakai H., and Abe M. Method of liposomes using supercritical carbon dioxide. Langmuir 17 (2001) 3898-3901
39. Kent J., Thomas L.A., Anders F.V., Huiling M., and Xuebing X. Oxidative stability of liposomes composed of docosahexaenoic acid-containing phospholipids. J. Am. Oil Chem. Soc. 84 7 (2007) 631-637
40. Kimelberg H.K., and Mayhew E.G. Properties and biological effects of liposomes and their uses in pharmacology and toxicology. Crit. Rev. Toxicol. 6 1 (1978) 25-79
41. Kompella U., and Koushik K. Preparation of drug delivery systems using supercritical fluid technology. Crit. Rev. Ther. Drug Carrier Syst. 18 2 (2001) 173-199
42. Konduri K., Nandedkar S., Rickaby D.A., Düzgüneş N., and Gangadharam P.R.J. The use of sterically stabilized liposomes to treat asthma. Methods Enzymol. 391 (2005) 413-427
43. Lu D., and Hickey A. Liposomal dry powders as aerosols for pulmonary delivery of proteins. AAPS PharmSciTech. 6 4 (2005) E641-E648
44. Maria L.I., Paola B., Flavio R., Silvia A., Maurizio C., and Luigi C. Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugs. J. Control. Release 100 (2004) 331-346
45. Markus M., Stefan M., Christel C., and Müller G. Physicochemical characterisation of liposomes with encapsulated local anaesthetics. Int. J. Pharm. 274 (2004) 139-148
46. Martin J.T., and Anthony J.H. Dry powder inhaler formulation. Respir. Care 50 9 (2005) 1209-1227
47. Mina A., Kanako Y., and Kazuo M. Oxidative stability of polyunsaturated fatty acid in phosphatidylcholine liposomes. Biosci. Biotechnol. Biochem. 66 12 (2002) 2573-2577
48. Misra A., Parmar N., Naik S., and Patel G. Preparation of Amphotericin B liposomes by supercritical fluid technology (2008) IN391/MUM/2008
49. New R.R.C. Liposomes-A Practical Approach (1990), Oxford University Press, New York 33-103
50. New R.R.C. Liposomes-A Practical Approach (1990), Oxford University Press, New York 105-160
51. Newman S.P. Dry powder inhalers for optimal drug delivery. Expert Opin. Biol. Ther. 4 1 (2004) 23-33
52. Newman S.P., and Clarke S.W. Therapeutic aerosols I-Physical and practical considerations. Thorax 38 (1983) 881-886
53. Niven R.W. Delivery of biotherapeutics by inhalation aerosol. Crit. Rev. Ther. Drug Carrier Syst. 12 (1995) 151-231
54. Oku N., and Namba Y. Glucuronate-modified, long-circulating liposomes for the delivery of anticancer agents. Methods Enzymol. 391 (2005) 145-162
55. Pang Y., Sakagami M., and Byron P.R. The pharmacokinetics of pulmonary insulin in the isolated perfused rat lung: Implications of metabolism and regional deposition. Eur. J. Pharm. Sci. 25 (2005) 369-378
56. Parmar M. Formulation of insoluble small molecule therapeutics in lipid-based carriers (2006) US20060051406A1
57. Patel G., and Misra A. Pulmonary delivery of liposomal dry powder inhaler of formoterol for effective treatment of asthma (2007). http://www.aapsj.org/abstracts/AM_2007/AAPS2007-001080.PDF
58. Robinson J.R., and Lee V.H.L. Controlled Drug Delivery: Fundamentals and Applications. 2nd edn. (1987), Marcel Dekker, New York
59. Sakagami M., Byron P.R., and Rypacek F. Biochemical evidence for transcytotic absorption of polyaspartamide from the rat lung: Effects of temperature and metabolic inhibitors. J. Pharm. Sci. 91 (2002) 1958-1968
60. Sakagami M., Byron P.R., Venitz J., and Rypacek F. Solute disposition in the rat lung in vivo and in vitro: Determining regional absorption kinetics in the presence of mucociliary clearance. J. Pharm. Sci. 91 (2002) 594-694
61. Sakagami M., Byron P.R., Venitz J., and Rypacek F. In vivo, in vitro, and ex vivo models to assess pulmonary absorption and disposition of inhaled therapeutics for systemic delivery. Adv. Drug Deliv. Rev. 50 9-10 (2006) 1030-1060
62. Shah S.P., and Misra A. Development of liposomal Amphotericin B dry powder inhaler formulation. Drug Deliv. 11 4 (2004) 247-253
63. Shah S.P., and Misra A. Liposomal amikacin dry powder inhaler: Effect of fines on in vitro performance. AAPS PharmSciTech. 5 4 (2004) E65
64. Shah S.P., and Misra A. Liposomal amphotericin B dry powder inhaler: Effect of fines on in vitro performance. Pharmazie 59 10 (2004) 812-813
65. Shah V.P., Elkins J.S., and Williams R.L. In vitro drug release measurement of topical glucocorticoid creams. Pharmacopeial Forum 19 (1993) 5048-5059
66. Shahiwala A., and Misra A. Pulmonary absorption of liposomal levonorgestral. AAPS PharmSciTech. 5 1 (2004) E13
67. Shahiwala A., and Misra A. A preliminary pharmacokinetic study of liposomal leuprolide dry powder inhaler: A technical note. AAPS PharmSciTech. 6 3 (2005) E482-E486
68. Shek P.N., and Barber R.F. Liposomes: A new generation of drug and vaccine carriers. Mod. Med. 41 (1986) 314-326
69. Singh S. Drug stability testing and shelf life determination according to international guidelines. Pharm. Technol. 23 (1999) 68-86
70. Sunkara G., and Kompella U. Drug delivery applications of supercritical fluid technology. Drug Deliv. Technol. 2 (1999) 33-34
71. Sweeney L., Wang Z., Loebenberg R., Wong J.P., Lange C.F., and Finlay W. Spray-freeze-dried liposomal ciprofloxacin powder for inhaled aerosol drug delivery. Int. J. Pharm. 305 1-2 (2005) 180-185
72. Taylor K.M.G., and Newton J.M. Liposomes for controlled delivery of drugs to the lung. Thorax 47 (1992) 257-259
73. Tronde A., Norden B., Jeppsson A.B., Brunmark P., Nilsson E., Lennernas H., and Bengtsson U.H. Drug absorption from the isolated perfused rat lung-Correlations with drug physicochemical properties and epithelial permeability. J. Drug Target 11 1 (2003) 61-74
74. Vyas S.P., Quraishi S., Gupta S., and Jaganathan K.S. Aerosolized liposome-based delivery of amphotericin B to alveolar macrophages. Int. J. Pharm. 296 (2005) 12-25
75. Woolfe A.J., Zheng X.M., and Langford A. Methods to produce powders for pulmonary or nasal administration (2001) WO0113885